Letter | Published:

ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase

Nature 282, 517–518 (29 November 1979) | Download Citation

Subjects

Abstract

The potent inducer of platelet aggregation, ADP, inhibits both basal and stimulated cyclic AMP production in intact platelets1,2. However, several attempts have failed to detect an effect of the nucleotide on adenylate cyclase activity in broken cell preparations2,3. This paradox has led to suggestions that ADP may act on unidentified sites before the adenylate cyclase step, such as a nucleoside diphosphate kinase4 and a Ca2+ transport system5,6. It is difficult to demonstrate the effect of physiologically effective concentrations (0.1–5 µM) of ADP on a crude membrane preparation of adenylate cyclase because of the presence of nucleoside phosphohydrolase activities which may degrade either the substrate ATP or the putative effector ADP to products (such as ADP, AMP and adenosine) displaying diverse effects. A substrate regenerating system which converts ADP to ATP obviously provides no solution. The contamination by adenine nucleotides and catecholamines in widely used crude lysate preparations aggravates the problem7–9. Using a purified human platelet plasma membrane preparation, and the non-hydrolysable ATP analogue APP(NH)P as substrate, we have now demonstrated direct inhibition of adenylate cyclase by ADP in the physiologically effective concentration range. The inhibitory effect of ADP is immediate in onset and is equal to that produced by adrenaline; it is shared by ADP-βS (and 2′-deoxy ADP to some extent) but not by AP(CH2)P or other adenine nucleotides. The Ki, for ADP is ∼ 0.3 µM and maximal inhibition is observed at 2 µM

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

References

  1. 1.

    , & Ann. N.Y. Acad. sci. 185, 477–487 (1971).

  2. 2.

    , , , & Adv. cyclic Nucleotide Res. 9, 533–552 (1978).

  3. 3.

    & J. clin. Invest. 50, 131–141 (1971).

  4. 4.

    , , , & Ciba Fdn Symp. 35, 47–75 (1975).

  5. 5.

    , , & Biochim biophys. Acta 466, 429–440 (1977).

  6. 6.

    Ciba Fdn Symposium 35, 121–151 (1975).

  7. 7.

    Lee, G. R., Boggs, D. R., Bithell, T. C., Athens, J. W. & Foerster, J. (eds) Clinical Haematology 7th edn 372–408. (Kimpton, London, 1974).

  8. 8.

    , & FEBS Lett. 85, 167–170 (1978).

  9. 9.

    , & Biochem. J. 176, 83–95 (1978).

  10. 10.

    & J. biol. Chem. 245, 6357–6365 (1970).

  11. 11.

    , & Analyt. Biochem. 58, 541–548 (1974).

  12. 12.

    & J. Chromatogr. 16, 111–129.

  13. 13.

    & Biochim. biophys. Acta 373, 471–480 (1974).

  14. 14.

    , & Molec. Pharmac. 8, 170–177 (1972).

  15. 15.

    , & J. org. Chem. 30, 1517–1520 (1965).

  16. 16.

    , , & Proc. natn. Acad. Sci. U.S.A. 75, 5362–5366 (1978).

  17. 17.

    & J. biol. Chem. 254, 1913–1920 (1979).

  18. 18.

    J. Physiol., Lond. 209, 487–511 (1970).

  19. 19.

    & Proc. natn. Acad. Sci. U.S.A. 74, 5482–5486 (1977).

  20. 20.

    in Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides (eds Baer, H. P. & Drummond, G. I.) 3–32 (Raven, New York, 1979).

  21. 21.

    , , & J. biol. Chem. 250, 4246–4252 (1975).

Download references

Author information

Affiliations

  1. Section on Membrane Regulation, Laboratory of Nutrition and Endocrinology, NIAMDD, NIH, Bethesda, Maryland 20205

    • Dermot M. F. Cooper
    •  & Martin Rodbell

Authors

  1. Search for Dermot M. F. Cooper in:

  2. Search for Martin Rodbell in:

To obtain permission to re-use content from this article visit RightsLink.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/282517a0

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.